Entrada Therapeutics, Inc. (TRDA)

NGM – Real Time Price. Currency in USD

7.67

+0.63 (8.95%)

At close: Aug 12, 2026, 4:00 PM EDT

7.67

0.00 (0.00%)

After-hours: Aug 12, 2026, 4:10 PM EDT

05.08.2026

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.

05.08.2026

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.

Videos

No Data

There is no data to display

Press releases

05.08.2026

Entrada Therapeutics, Inc. (TRDA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Search stocks

Entrada Therapeutics, Inc. (TRDA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

Entrada Therapeutics Reports Second Quarter 2026 Financial Results